Sagent Pharmaceuticals, Inc. Vecuronium Bromide for Injection Safety Data Sheet (SDS) SDS Issue Date: Feb. 16, 2015 SDS No.: SDS Version No.: Form No.: R-SOP-009-F001 1 of 10

Section 1 - Identification

(a) **Product Identifier:** Vecuronium Bromide for Injection (10 mg and 20 mg/vial)

(b) Product Code: 25021-657, 25021-658

Common/Trade Name: Norcuron®

Chemical Name: Vercuronium Bromide

Chemical Family: Amino-Steroid

(c) **Product Use:** Neuromuscular blocking agent **Product Type:** Regulated Prescription Drug

Container Information: Vials

(d) **Distributor:** Sagent Pharmaceuticals, Inc., 1901 N. Roselle Rd, Suite 700,

Schaumburg, IL 60195, 847-908-1600

(e) Emergency Telephone: 866-625-1618

Section 2 - Hazards Identification

(a) Classification: <u>US OSHA:</u> Target Organ Toxin, Possible Irritant

(b) Signal Word, Hazard	(c) Description of Hazards:
statement(s), Symbol(s),	
and/or Precautionary	
statement(s):	
Signal Word:	- Not available
Hazard Statements:	

<u>Hazard Statements:</u>

- Non-hazardous in accordance with international standards for workplace safety

GHS Precautionary Statements

Prevention

- P260: Do not breathe dust/fume/vapors/spray

Response

- IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists, get medical advice/attention
- Get medical attention if you feel unwell

Sagent Pharmaceuticals, Inc.					
Vecuronium Bromide for Injection			Safety Data Sheet (SDS)		
SDS Issue Date: Feb. 16, 2015	SDS No.: SDS 024	SDS Version No.: 3.0	Form No.: R-SOP-009-F001	Page: 2 of 1	

(d) Unknown Acute Toxicity: N/A

Section 3 – Composition / Information on Ingredients

Page: **2 of 10**

(a) Chemical Name	(b) Common Name / Synonym	% Composition or other measure	(c) CAS No.	(d) Impurities / Stabilizing Additives
[(2 <i>S</i> ,3 <i>S</i> ,5 <i>S</i> ,8 <i>R</i> ,9 <i>S</i> ,10 <i>S</i> ,13 <i>S</i> ,14 <i>S</i> ,16 <i>S</i> ,17 <i>S</i>)- 17-Acetyloxy-10,13-dimethyl-16-(1- methyl-3,4,5,6-tetrahydro-2 <i>H</i> -pyridin- 1-yl)-2-(1-piperidyl)- 2,3,4,5,6,7,8,9,11,12,14,15,16,17- tetradecahydro-1 <i>H</i> - cyclopenta[a]phenanthren-3-yl] acetate bromide	Vercuronium Bromide, USP	7% (w/w)	50700- 72-6	N/A
Sodium hydrogen phosphate	Sodium Phosphate, Dibasic Anhydrous	11% (w/w)	7558-79- 4	N/A
2-hydroxypropane-1,2,3-tricarboxylic acid	Citric Acid Anhydrous	14% (w/w)	77-92-9	N/A
(2R,3R,4R,5R)-Hexan-1,2,3,4,5,6-hexol	Mannitol, NF	67% (w/w)	69-65-8	N/A
Sodium Hydroxide	Sodium Hydroxide, NF	Trace	1310-73-	N/A
trihydroxidooxidophosphorus phosphoric acid	Phosphoric Acid, NF	Trace	7664-38- 2	N/A

Section 4 - First Aid Measures

Eye Exposure: Flush eyes with large volumes of water for 15 minutes.

Skin Exposure: Wash skin with cool, soapy water for 15 minutes; remove

contaminated clothing.



Sagent Pharmaceuticals, Inc.					
Vecuronium Bromide for Injection			Safety Data Sheet (SDS)		
SDS Issue Date: Feb. 16, 2015	SDS No.: SDS 024	Form No.: R-SOP-009-F001	Page: 3 of 10		

Ingestion:

If swallowed, seek emergency medical attention. If victim is drowsy or unconscious and vomiting, place on the left side with the head down and DO NOT give anything by mouth. If not vomiting and professional advice is not available, DO NOT induce vomiting. If possible, do not leave victim unattended and observe closely for adequacy of breathing.

Victims of chemical exposure must be taken for medical attention. Take a copy of the MSDS to the physician or health professional with

victim. Physicians should refer to Section 11 (Toxicological

Information) as well as the Physicians Desk Reference for additional

treatment information

Injection: See patient package insert in shipping carton for complete information.

Inhalation: If respiratory symptoms develop, move victim away from source of

exposure and into fresh air. If symptoms persist, seek medical attention. If victim is not breathing, clear airway and immediately begin artificial respiration. If breathing difficulties develop, oxygen should be administered by qualified personnel. Seek immediate

medical attention.

Notes to Physician: See patient package insert in shipping carton for complete information.

Section 5 – Fire-fighting Measures

(a) **Extinguishing Media** Use water or a type ABC multi-purpose extinguisher.

(b) Hazardous None

Combustion Products:

(c) Special Protective As with all fires, evacuate personnel to a safe area. Fire

Equipment / fighters should wear self-contained breathing apparatus to

Precautions: avoid inhalation of smoke.

Section 6 - Accidental Release Measures

Spill: Lightly wet Vecuronium Bromide powder and absorb with a damp

absorbent cloth. Dispose according to local, state and federal

regulations. Wear latex or nitrile gloves.

Release to Air: If dust enters air, reduce exposures by ventilating the area; clean up the

spill immediately.

Sagent Pharmaceuticals, Inc. Vecuronium Bromide for Injection Safety Data Sheet (SDS) SDS Issue Date: Feb. 16, 2015 SDS No.: SDS No.: SDS Version No.: R-SOP-009-F001 Page: 4 of 10

Release to Water: Refer to local water authority. Drain disposal is not recommended; refer to local, state, and federal disposal guidelines.

Section 7 - Handling and Storage

General Handling:

As with all chemicals, avoid getting this product ON YOU or IN YOU. Do not eat, drink, smoke or apply cosmetics while handling the product. Wash hands thoroughly after handling.

Particular care in working with this product must be practiced in pharmacies and other preparation areas, during manufacture of this product, and during patient administration. Precautions should be taken during the following activities:

- ➤ Withdrawal of needles from drug vials.
- > Drug transfers using syringes and needles or filter straws.

Expulsion of air from drug-filled syringes.

Storage Conditions:

Employees must be trained to properly use the product. Ensure vials are properly labeled. Store only in approved containers. Protect from light. Keep away from any incompatible materials or conditions (see Section 10). Store at temperatures between 15-30°C (59-86°F).

Section 8 - Exposure Controls / Personal Protection

(a) Exposure Limits

Compound	Issuer	Type	Exposure Limit
Vercuronium Bromide	OSHA	PEL	NE
	ACGIH	TLV	NE
		STEL	NE
Citric Acid Anhydrous	OSHA	PEL	NE
	ACGIH	TLV	NE
		STEL	NE
Sodium Phosphate Dibasic	OSHA	PEL	NE
Anhydrous	ACGIH	TLV	NE
		STEL	NE
Mannitol	OSHA	PEL	NE
	ACGIH	TLV	NE
		STEL	NE

Sagent Pharmaceuticals, Inc.					
Vecuronium Bromide	for Injectio	n	Safety Data Sheet ((SDS)	
SDS Issue Date: Feb. 16, 2015	SDS No.: SDS 024	SDS Version No.: 3.0	Form No.: R-SOP-009-F001	Page: 5 of 1	

(b) Engineering Controls

Ventilation: Use with adequate ventilation such as a Class II Type A Biological

Page: **5 of 10**

Safety Cabinet.

(c) Individual Protection Measures

Respiratory Protection:	Under normal use, respirators are not needed.
Eye Protection:	Approved eye protection to safeguard against potential eye contact, irritation or injury is recommended. Depending on conditions of use, a face shield may be necessary.
Skin Protection:	Use latex, nitrile, or rubber gloves. Check gloves for leaks. Wash hands before and after using gloves.
Other Protective Equipment:	None
Additional Exposure Precautions:	No special body protection required for routine, medical administration of this product. Wear lab coat, gown, or smock, as appropriate for procedure.

Section 9 - Physical and Chemical Properties

(a)	Appearance	Solid white powder
(b)	Odor	No Odor
(c)	Odor Threshold	None
(d)	рН	3.5 – 4.5
(e)	Melting Point:	227-229°C
(f)	Initial Boiling Point:	Not available
(g)	Flash Point	Not established
(h)	Evaporation Rate:	Not applicable
(i)	Flammability	Not established
(j)	Upper Lower Flammability or Explosion Limits	Not established
(k)	Vapor Pressure:	Not applicable



Sagent Pharmaceuticals, Inc. Vecuronium Bromide for Injection Safety Data Sheet (SDS) SDS Issue Date: Feb. 16, 2015 SDS No.: SDS Version No.: R-SOP-009-F001 Page: R-SOP-009-F001

(l)	Vapor Density:	Not applicable
(m)	Relative Density	Not applicable
(n)	Solubility(ies)	Soluble in water
(o)	Partition Coefficient: n-octanol/water	Not available
(p)	Auto-ignition Temperature	Not established
(q)	Decomposition Temperature	Not available
(r)	Viscosity	Not available

Section 10 - Stability and Reactivity

(a)	Reactivity	Not Reactive		
(b)	Chemical Stability	Stable under normal storage handling conditions.		
(c)	Possibility of Hazardous Reactions	Will not occur.		
(d)	Conditions to Avoid	None		
(e)	Incompatible Materials	This product is generally compatible with other common materials in a medical facility. Keep away from strong acids, strong bases and strong oxidizers.		
(f)	Hazardous Decomposition Products	Heat may cause product to decompose, destroying the product or producing toxic fumes.		

Section 11 - Toxicological Information

(a)	Likely Routes of Exposure	Skin, ingested and inhalation	
(b)	Symptoms related to the physical, chemical and toxicological characteristics	Vecuronium is a drug product that is a smooth muscle relaxer used in association with general anesthesia when intubating patients. It affects the central nervous system and muscular systems.	
(c)	Delayed and immediate effects and also chronic effects from short and long term exposure	Excessive exposure may induce paralysis with risks for respiratory failure and vomiting. It may also cause irritation of eyes, skin and respiratory tract. May cause dizziness, headache, weakness and loss of coordination.	

Sagent Pharmaceuticals, Inc. Vecuronium Bromide for Injection Safety Data Sheet (SDS) SDS Issue Date: Feb. 16, 2015 SDS No.: SDS No.: SDS Version No.: R-SOP-009-F001 Page: R-SOP-009-F001 7 of 10

(d) Acute Toxicity

Component	Type	Route	Species	Dosage
Vecuronium	LD ₅₀	Oral	Rat	455 mg/kg
Bromide				
Vecuronium	LD ₅₀	Oral	Mouse	41 mg/kg
Bromide				
Vecuronium	LD ₅₀	Interperatoneal	Rat	2630 mcg/kg
Bromide				
Vecuronium	LD ₅₀	Intraperatoneal	Mouse	142 mcg/kg
Bromide		_		
Vecuronium	TD_{LO}	Oral	Woman	130 mcg/kg
Bromide				
Vecuronium	LD ₅₀	Subcutaneous	Rat	1730 mcg/kg
Bromide				
Vecuronium	LD_{50}	Intravenous	Rat	200 mcg/kg
Bromide				
Vecuronium	LD ₅₀	Intravenous	Mouse	50 mcg/kg
Bromide				
Citric Acid	LD ₅₀	Oral	Rat	11700 mg/kg
Citric Acid	LD ₅₀	Oral	Mouse	5040 mg/kg
Citric Acid	LD ₅₀	Intravenous	Mouse	43 mg/kg
Citric Acid	LD ₅₀	Intravenous	Rabbit	330 mg/kg
Mannitol	LD ₅₀	Oral	Mouse	22,000 mg/kg
Mannitol	LD ₅₀	Intravenous	Mouse	7470 mg/kg
Mannitol	LD_{50}	Oral	Rat	13,500 mg/kg
Mannitol	LD ₅₀	Intravenous	Rat	9690 mg/kg
Dibasic Sodium	LD ₅₀	Oral	Rat	17,000 mg/kg
Phosphate				

Additional reproductive health and toxicity data is available from the National Institute for Occupational Safety and Health (NIOSH) Registry of Toxic Effects of Chemical Substances (RTECS)

(e) Hazardous Chemical Listings

NTP: Not Listed IARC: Not Listed OSHA: Not Listed

SI

Sagent Pharmaceuticals, Inc.					
Vecuronium Bromide for Injection			Safety Data Sheet (SDS)		
SDS Issue Date: Feb. 16, 2015	SDS No.: SDS 024	SDS Version No.: 3.0	Form No.: R-SOP-009-F001	Page: 8 of 10	

Section 12 - Ecological Information

(a)	Ecotoxicity	Not a DOT Hazardous Material or Marine Pollutant	
(b)	Persistence and degradability	Not a DOT Hazardous Material or Marine Pollutant	
(c)	Bioaccumulative potential	Not a DOT Hazardous Material or Marine Pollutant	
(d)	Mobility in soil	Not a DOT Hazardous Material or Marine Pollutant	
(e)	Other Adverse Effects	Not a DOT Hazardous Material or Marine Pollutant	

Section 13 - Disposal Considerations

Incineration in an approved/permitted incinerator is recommended. Refer to local, state, and federal disposal guidelines.

Section 14 - Transport Information

(a)	UN Number	Not available
(b)	UN Proper Shipping Name	Not available
(c)	Transport Hazard Class(es)	Not available
(d)	Packing Group	Not available
(e)	Environmental Hazards	Not available
(f)	Transport in bulk (according to Annex II of MARPOL 73/78 and the IBC Code)	Not available
(g)	Special Precautions	Not available

DOT: Not regulated

ICAO/IATA: Not regulated

IMDG: Not regulated

Section 15 - Regulatory Information

Below is selected regulatory information chosen primarily for possible Sagent usage. This section is not a complete analysis or reference to all applicable regulatory information. Please consider all applicable laws and regulations for your country/state.

U.S. Regulations:

TSCA – Citric Acid, Mannitol, and Dibasic Sodium Phosphate are listed CERCLA - Not on this list SARA 302 - Not on this list SARA 313 - Not on this list OSHA Substance Specific - No

Section 16 - Other Information

As of the date of issuance, we are providing available information relevant to the handling of this material in the workplace. All information contained herein is offered with the good faith belief that it is accurate. THIS SAFETY DATA SHEET SHALL NOT BE DEEMED TO CREATE ANY WARRANTY OF ANY KIND (INCLUDING WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE). In the event of an adverse incident associated with this material, this safety data sheet is not intended to be a substitute for consultation with appropriately trained personnel. Nor is this safety data sheet intended to be a substitute for product literature which may accompany the finished product.

For additional information contact: Sagent Pharmaceuticals, Inc. 1901 N. Roselle Rd, Suite 700 Schaumburg, IL 60195 847-908-1600

Glossary: This glossary contains definitions of general terms used in SDSs. Not all of these Glossary Terms will apply to this SDS.

ACGIH	American Conference of Governmental Industrial Hygienists
AICS	Australian Inventory of Chemical Substances
AIHA	American Industrial Hygiene Association
ANSI	American National Standards Institute
CAS Number	Chemical Abstract Service Registry Number
CERCLA	Comprehensive Environmental Response Compensation and Liability Act (of 1980)
CHAN	Chemical Hazard Alert Notice
CHEMTREC	Chemical Transportation Emergency Center
DOT	Department of Transportation
DSL	Domestic Substances List
ECHA	European Chemicals Agency



Sagent Pharmaceuticals, Inc. Vecuronium Bromide for Injection SDS Issue Date: Feb. 16, 2015 SDS No.: SDS Version No.: SDS Version No.: SDS Version No.: R-SOP-009-F001 Page: 10 of 10

EINECS	European Inventory of Existing Commercial Chemical Substances	
ELINCS	European List of Notified Chemical Substances	
EPA	Environmental Protection Agency	
GHS	Globally Harmonized System of Classification and Labelling of Chemicals	
HEPA	High Efficiency Particulate Air (Filter)	
HMIS	Hazardous Materials Identification System	
IARC	International Agency for Research on Cancer	
ICAO/IATA	International Civil Aviation Organization/International Air Transport Association	
IMDG	International Maritime Dangerous Goods	
IMO	International Maritime Organization	
KOW	Octanol/Water Partition Coefficient	
LEL	Lower Explosive Limit	
MSDS	Material Safety Data Sheet	
MSHA	Mine Safety and Health Administration	
NA	Not Applicable, except in Section 14 where NA = North America	
NE	Not Established	
NADA	New Animal Drug Application	
NAIF	No Applicable Information Found	
NCI	National Cancer Institute	
NDSL	Non-Domestic Substances List	
NFPA	National Fire Protection Association	
NIOSH	National Institute for Occupational Safety and Health	
NPDES	National Pollutant Discharge Elimination System	
NOS	Not Otherwise Specified	
NTP	National Toxicology Program	
OSHA	Occupational Safety and Health Administration	
OEL	Occupational Exposure Limit	
PEL	Permissible Exposure Limit (OSHA)	
RCRA	Resource Conservation and Recovery Act	
RQ	Reportable Quantity	
RTECS	Registry of Toxic Effects of Chemical Substances	
SARA	Superfund Amendments and Reauthorization Act	
SDS	Safety Data Sheet	
STEL	Short Term Exposure Limit	
TLV	Threshold Limit Value (ACGIH)	
TPQ	Threshold Planning Quantity	
TSCA	Toxic Substances Control Act	
TWA	Time Weighted Average/8 Hours Unless Otherwise Noted	
UEL	Upper Explosive Limit	
UN	United Nations	
USP	United States Pharmacopeia	
WEEL	Workplace Environmental Exposure Level (AIHA)	
WHMIS	Workplace Hazardous Materials Information System	